The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

- Large, Randomized Controlled ADVENT Trial Designed to Establish New Gold Standard for AF Ablation - MENLO PARK, Calif., Dec. 17, 2020/PRNewswire/ - FARAPULSE Inc. ("FARAPULSE" or "the Company") ...

Boston Scientific had a lot to celebrate this morning, as the announcement of an FDA green light for its pulsed field ablation system coincided with the company’s fourth-quarter earnings release, ...

Boston Scientific Corp BSX will present results from ADVENT pivotal trial for its Farapulse Pulsed Field Ablation (PFA) system at the 2023 European Society of Cardiology Congress on 27 August. ADVENT ...

Add Yahoo as a preferred source to see more of our stories on Google. KINGSPORT, Tenn. (WJHL) – On Wednesday, Holston Valley Medical Center (HVMC) successfully performed a cardiac ablation procedure ...

Despite Boston Scientific’s pulse field ablation (PFA) system Farapulse demonstrating strong efficacy from the FARADISE registry study, the trial’s principal investigator says that data also indicated ...

Narrow-moat Boston Scientific’s BSX long-awaited clinical data on its Farapulse pulsed field ablation, or PFA, device for atrial fibrillation didn’t disappoint, and we’ve raised our fair value ...

Steven Mickelsen, the electrophysiologist who founded Farapulse before it was sold to Boston Scientific in 2021, is taking pulsed field ablation into new territory with the development of a device ...

In December 2023, Boston Scientific Corporation (NYSE: BSX) initiated the AVANT GUARD trial to evaluate the safety and effectiveness of the FARAPULSE Pulsed Field Ablation (PFA) System as a first-line ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

MARLBOROUGH, Mass. and SAN DIEGO, April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of the ...

MARLBOROUGH, Mass. and AMSTERDAM, Aug. 27, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the ...